C.K. Wang, MD, senior medical director, COTA, explains how COTA's real-world data platform can benefit payers.
C.K. Wang, MD, senior medical director, COTA, explains how COTA's real-world data platform can benefit payers.
Transcript
COTA has announced that it will partner with Horizon Blue Cross Blue Shield of New Jersey. How can payers benefit from COTA’s real-world data platform?
I think it’s very important to understand that payers' current view of a patient’s medical treatment and cancer journey is through claims data, and for anyone familiar with claims data, it is often fragmented, incomplete, and can often times be not very accurate. COTA’s platform on the other hand, by exposing and bringing forth real-world data, can help lend a clear granular view into that patient’s treatment journey. We capture many treatment variables, including performance status, the cancer diagnosis, the cancer’s actual pathology make up, the treatment regimen, the drugs used, the toxicities, as well as the patient’s journey through their treatment history.
What COTA does is we then take that real-world data and we assign a specific code to the patient, called the CNA [Cota Nodal Address]. What the CNA essentially serves as is it allows a provider or allows any entity to view patients by their groupings, and patients with identical CNAs are technically clinically similar patients that should have been treated very similarly, and hopefully have very similar outcomes. With the use of CNA in conjunction with claims data, all of a sudden, payers are now given a clear view into what truly happens to a patient .What we’re finding is payers can then use this information, or the healthcare system can use this information to help payers understand the multiple variables that take place in a patient’s treatment, and in the current day of the ever increasing cost of cancer care, I think we’re seeing that payers are very excited to use the CNA and to use also real-world data in an attempt to work with providers to help control costs.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More